Q-omics provides the consensus-scored SMCO2 profile across patient tissues and cancer cell-line models. SMCO2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, SMCO2 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, SMCO2 RNA expression shows 11,693 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight MESO, HNSC, and BLCA as cancer lineages where SMCO2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMCO2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMCO2 survival associations across molecular data types. SMCO2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMCO2 RNA expression–survival associations across cancer types. High SMCO2 expression shows unfavorable associations in MESO, PAAD, UVM, LGG and LIHC, but favorable associations in COAD. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for SMCO2 RNA expression.
This table summarizes SMCO2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SMCO2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMCO2 shows higher tumor expression in HNSC, BLCA, COAD, LUSC, LUAD and BRCA. The HNSC box plot shows higher SMCO2 RNA expression in tumor versus normal tissue (log2 FC = +0.716, t-test p < 0.001).
This table shows molecular features associated with SMCO2 in patient tissues and cancer cell lines. In patient samples, SMCO2 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set. In cancer cell lines, SMCO2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Lymphoma.
